Article
Cell Biology
Ming-Yii Huang, Yi-Jung Huang, Tian-Lu Cheng, Wun-Ya Jhang, Chien-Chih Ke, Yi-Ting Chen, Shih-Hsun Kuo, I-Ling Lin, Yu-Hsiang Huang, Chih-Hung Chuang
Summary: This study investigated the effects of XPF-ERCC1 blockers on chemotherapy and chemoradiotherapy using 5-FU or oxaliplatin in colorectal cancer. The results showed that XPF-ERCC1 blockers reduced the cytotoxicity of chemotherapy drugs and enhanced the efficacy of chemoradiotherapy. These findings suggest that XPF-ERCC1 blockers may improve the effectiveness of 5-FU and oxaliplatin-based chemoradiotherapy.
Article
Biochemistry & Molecular Biology
Changwon Yang, Jisoo Song, Sunjae Hwang, Jungil Choi, Gwonhwa Song, Whasun Lim
Summary: The study found that apigenin enhances the inhibitory effect of 5-FU on colorectal cancer cells by suppressing TS expression, promoting apoptosis, and disrupting the cell cycle. Additionally, apigenin increases reactive oxygen species production and intracellular calcium levels, indicating its potential to improve therapeutic efficacy.
Article
Biochemistry & Molecular Biology
Changwon Yang, Jisoo Song, Sunwoo Park, Jiyeon Ham, Wonhyoung Park, Hahyun Park, Garam An, Taeyeon Hong, Hee Seung Kim, Gwonhwa Song, Whasun Lim
Summary: This study investigated the effects of quercetin on colorectal cancer cells and found that quercetin can suppress thymidylate synthase levels and induce oxidative stress and calcium dysregulation. It also regulates the expression of specific tiRNAs and enhances apoptosis in CRC cells. Quercetin treatment in colitis-associated CRC mice showed enhanced sensitivity to 5-FU and reduced tumor growth. These findings suggest that quercetin has the potential to be used as an adjuvant with 5-FU for the treatment of CRC.
Article
Medicine, General & Internal
Zhicheng Lai, Yexing Huang, Dongsheng Wen, Xuanjia Lin, Anna Kan, Qijiong Li, Wei Wei, Minshan Chen, Li Xu, Minke He, Ming Shi
Summary: This study compared the efficacy and safety of one-day and two-day HAIC regimens in treating hepatocellular carcinoma (HCC) and explored the predictive power of thymidylate synthase (TYMS).
Article
Health Care Sciences & Services
Young-Joo Jeon, Sung-Hwan Cho, Eo-Jin Kim, Chang-Soo Ryu, Han-Sung Park, Jong-Woo Kim, Jeong-Yong Lee, Hui-Jeong An, Nam-Keun Kim
Summary: This study found an association between 3'-UTR variants in TS genes and colorectal cancer, suggesting they could potentially serve as biomarkers for CRC prognosis and prevention.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Marie Malier, Khaldoun Gharzeddine, Marie-Helene Laverriere, Sabrina Marsili, Fabienne Thomas, Thomas Decaens, Gael Roth, Arnaud Millet
Summary: The study reveals that macrophages specifically overexpress DPD in hypoxia, leading to macrophage-induced chemoresistance to 5-FU, while tumor cells do not express significant levels of DPD. These findings shed light on the crucial role of TAMs in promoting chemoresistance in colorectal cancers.
Article
Biochemistry & Molecular Biology
Chinatsu Kurasaka, Yoko Ogino, Akira Sato
Summary: This study identified that 5-FU-resistant cells exhibit increased TS expression and utilize the TS enzyme to trap the active metabolite FdUMP, resulting in resistance to 5-FU and its analogs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biology
Kuen-Lin Wu, Ko-Chao Lee, Chia-Kuang Yen, Cheng-Nan Chen, Shun-Fu Chang, Wen-Shih Huang
Summary: The study found that visfatin significantly reduces CRC sensitivity to capecitabine by controlling TYMS expression, while resveratrol can significantly alleviate the visfatin effect on capecitabine-treated CRC cells. These results provide new insights into understanding capecitabine susceptibility of CRC under a visfatin-containing environment and suggest a potential therapeutic application of resveratrol in CRC patients with obesity.
Article
Biochemistry & Molecular Biology
Yong-Hwi Kang, Jin-Seok Lee, Nam-Hun Lee, Seung-Hyung Kim, Chang-Seob Seo, Chang-Gue Son
Summary: Colorectal cancer (CRC) is the third most common cancer worldwide among both men and women, with early detection and resection being the best treatment and chemotherapy a main treatment option. Coptidis Rhizoma extract (CRE) shows potential as an adjuvant agent against 5-FU-resistant colorectal cancers by reducing cell viability and inhibiting thymidylate synthase (TS) expression.
Article
Oncology
Yi-Jung Huang, Ming-Yii Huang, Tian-Lu Cheng, Shih-Hsun Kuo, Chien-Chih Ke, Yi-Ting Chen, Yuan-Chin Hsieh, Jaw-Yuan Wang, Chiu-Min Cheng, Chih-Hung Chuang
Summary: This study investigated the functionality and stability of ERCC1 using the Tet-on gene expression system. The results showed that overexpression of ERCC1 increased radioresistance in colorectal cancer cells and was highly correlated with radiotherapeutic efficiency. Furthermore, ERCC1 overexpression also promoted cell migration under radiation exposure. Additional experiments confirmed the increased cancer radiation resistance associated with ERCC1 overexpression. Therefore, ERCC1 overexpression may serve as a prognostic marker for colorectal cancer patients undergoing concurrent chemoradiotherapy.
Review
Oncology
Adarsh Kumar, Ankit Kumar Singh, Harshwardhan Singh, Suresh Thareja, Pradeep Kumar
Summary: Thymidylate synthase is a crucial enzyme for DNA synthesis, and its overexpression leads to drug resistance in cancer cells. This review summarizes different approaches for regulating thymidylate synthase to overcome resistance in colorectal cancer.
Article
Oncology
Anant Ramaswamy, Vikas Ostwal, Atul Sharma, Prabhat Bhargava, Sujay Srinivas, Mahesh Goel, Shraddha Patkar, Sarika Mandavkar, Poonam Jadhav, Manali Parulekar, Amitkumar Choudhari, Sudeep Gupta
Summary: This study found that the use of CAPIRI regimen did not improve overall survival compared to irinotecan alone in patients with advanced gallbladder cancer who had received treatment with a gemcitabine-platinum regimen. More patients in the CAPIRI group required dose modification compared to those in the irinotecan group.
Article
Chemistry, Medicinal
Gang Dong, Yu-heng Li, Jing-si Guo, Qi-qi Lin, Mei-yan Deng, Wen-han Xue, Xin-yan Li, Fan-hao Meng
Summary: Based on previous work, this study focused on the further search for more effective and less damaging inhibitors of thymidylate synthase (TS). A series of (E)-N-(2-benzyl hydrazine-1-carbonyl) phenyl-2,4-deoxy-1,2,3,4-tetrahydro pyrimidine-5-sulfonamide derivatives were synthesized and reported for the first time after structural optimization. The compound DG1 showed potential as a TS inhibitor for treating NSCLC angiogenesis, as it exhibited direct binding to TS proteins, promoted apoptosis in cancer cells, and inhibited cancer tissue proliferation and angiogenesis.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Pharmacology & Pharmacy
Robert B. Diasio, Federico Innocenti, Steven M. Offer
Summary: There are approximately 20 effective drugs for treating colorectal cancer, including cytotoxic drugs, targeted therapeutics, and combination therapies. Targeted therapeutics can include monoclonal antibodies, fusion proteins, and small molecule drugs. The first drug introduced for clinical use was 5-fluorouracil in the early 1960s, which remains a foundation for many CRC treatments.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Vipul Panchal, Sushil Kumar, Shaikh Nausad Hossain, Dileep Vasudevan
Summary: This study presents the first thymidylate synthase (TS) structure from a crustacean virus, highlighting its distinction from shrimp and other TS structures, providing important insights for further research.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)